Developer docs
API playgroundTry for free, no card

Search company profiles

Bloomlife

Full company profile

uuid0000a6l

Namestring
Bloomlife
Legal namestring
Bloomlife, Inc.
Websiteurl
bloom-life.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Bloomlife is a women's health technology company that has built a remote patient monitoring (RPM) platform for high-risk pregnancies. Founded in 2014 by Eric Dy and Julien Penders after Dy experienced a high-risk pregnancy in his own family, the company develops cellular-enabled, FDA-cleared medical devices for blood pressure, blood glucose, and patch-based fetal monitoring that transmit data directly to providers without requiring patient WiFi or smartphone apps. The core product, Bloomlife Connects, integrates these device modules with a Health Screening component (PHQ-9, EPDS, social determinants of health assessments), an AI-based digital biomarker for labor onset detection, configurable smart notifications, and native EMR integration.

The company targets OB/GYNs, maternal-fetal medicine specialists, women's health practices, and health systems in the United States, with engineering and clinical study operations in Liège, Belgium and Eindhoven, Netherlands. Its business model is reimbursement-driven: the RPM program is offered to providers at no upfront cost and no commitment, with device costs bundled into existing CPT-coded remote patient monitoring reimbursement covered by 19 in-network commercial payers plus Medicaid. Customer references include UCHealth, Ochsner Health System, Oregon Health Science University, Valley Perinatal Services, Unified Women's Healthcare, and Advantia Health.

Bloomlife has raised approximately $29M cumulatively across disclosed rounds from 2015 through September 2024, including a $12.9M round in September 2024, with investors including SOSV HAX, Plug and Play, Kapor Capital, Noshaq (Meusinvest), SFPIM, and RH Capital. The company holds 15 patents and 19 peer-reviewed publications supporting its clinical evidence base, has received FDA 510(k) clearance for its fetal monitor (K222327), and maintains SOC 2 Type II and HIPAA compliance for enterprise-grade deployment.

Short descriptiontext

Bloomlife provides a cellular-enabled, FDA-cleared remote patient monitoring platform for high-risk pregnancies, targeting OB/GYNs, maternal-fetal medicine specialists, and US health systems with reimbursable blood pressure, blood glucose, and fetal monitoring.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote patient monitoring, maternal health monitoring, fetal heart monitoring, connected care platform, pregnancy care solutions
Industry4 codes
PRIMARYHLALAFAG
Maternal & High-Risk Pregnancy Remote Monitoring (BP, glucose, fetal/uterine monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAPAG
Maternal, Neonatal & Pediatric Remote Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAF
Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SIC code1 code
  • Services-Home Health Care Services8082
Product category
Maternal Health Remote Monitoring
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Remote Patient Monitoring Reimbursement
TypeSubscription Recurring
Description

Bloomlife's primary revenue stream comes from Remote Patient Monitoring reimbursement covered by Medicaid and commercial payers using existing CPT codes. The program includes cellular-enabled FDA-cleared monitoring devices where the cost of devices (blood pressure cuff and blood glucose device) is included in the remote patient monitoring reimbursement with no additional costs charged to the practice or patient.

bloom-life.com
2Equity Securities Offering
TypeLicensing Royalties
Description

SEC Form D filing indicates an exempt offering of securities raising approximately $14.9 million with equity securities and pooled investment fund interests.

sec.gov
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1RPM Program for Healthcare Providers
ModelSubscriptionBilling cadenceMulti-year contract
Notes

No upfront costs, no commitment required from providers. The program is fully reimbursable using existing CPT codes for remote patient monitoring. Device costs included in reimbursement.

bloom-life.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Bloomlife provides a connected care platform, Bloomlife Connects, for remote patient monitoring of high-risk pregnancies. The offering combines FDA-cleared cellular-enabled medical devices for blood pressure, blood glucose, and patch-based fetal monitoring with cloud-based analytics, EMR integration, customizable clinical protocols, and AI-based digital markers for labor detection. The program is sold to healthcare providers and is reimbursable under existing CPT codes for remote patient monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 260% improvement in adherence to home blood pressure screening with Bloomlife Connects compared to standard of care
+8 more records
Product overview1 text field

Bloomlife offers Bloomlife Connects, a comprehensive connected care platform for remote monitoring of high-risk pregnancies. The platform integrates multiple monitoring modules including Blood Pressure RPM (cellular-enabled, FDA-cleared blood pressure monitoring), Blood Glucose RPM (continuous glucose monitoring and finger stick support), Fetal Monitoring (patch-based home fetal non-stress testing with FDA 510(k) clearance), and Health Screening (PHQ-9 and EPDS mental health assessments). These modules work together to enable healthcare providers to assess maternal-fetal health outside the office, with automated data capture, configurable clinical protocols, smart notifications, and EMR integration.

Product and service1 record
1Bloomlife Connects
CategoryConnected Care Platform
Description

A comprehensive connected care platform that enables healthcare providers to remotely monitor high-risk pregnant patients. Includes FDA-cleared cellular-enabled blood pressure and blood glucose monitoring devices, the world's first patch-based home fetal monitoring solution (FDA 510(k) #K222327), and digital health screening assessments (PHQ-9, EPDS). Features cloud-based analytics, customizable care escalation protocols, smart notifications, native EMR integration, and AI-based digital markers for labor detection. Designed for healthcare providers including OB/GYN practices, MFM specialists, and health systems, and is reimbursable using existing CPT codes for remote patient monitoring.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierAdvisoryTypeStrategic or Co-development Partner
Description

March of Dimes Chief Medical Officer Amanda Williams, MD, MPH serves as an advisor to Bloomlife, providing expertise in women's health and maternal care improvement.

Strategic tierCustomerTypeTechnology or Integration
Description

Valley Perinatal Services is both a customer and advisory partner, with MFM Medical Director Ravi Gunatilake serving as a medical advisor. The practice uses Bloomlife Connects for remote monitoring of high-risk patients.

3Louisiana Perinatal Quality Collaborative
Strategic tierAdvisoryTypeStrategic or Co-development Partner
Description

Medical Director Veronica Gillispie-Bell, MD, MAS serves as a strategic advisor, bringing expertise in perinatal quality improvement and maternal health outcomes.

bloom-life.com
Strategic tierAdvisoryTypeStrategic or Co-development Partner
Description

Charlotte Owens, MD, Head of Medical Affairs and Outcomes Research at Organon, serves as an advisor bringing pharmaceutical and women's health industry expertise.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Babyscripts is a direct competitor offering a maternal remote patient monitoring platform for OB/GYN practices, including blood pressure monitoring, weight tracking, and virtual care. It targets the same provider customer base and reimbursement model as Bloomlife.

TypeDirect peer
Description

HeraMED develops remote fetal and maternal monitoring solutions, including at-home NST and contraction monitoring devices. It competes directly with Bloomlife in connected maternal-fetal monitoring for high-risk pregnancies.

TypeBroad incumbent
Description

Philips offers fetal monitoring hardware, maternal care solutions, and a broader remote patient monitoring portfolio through BioTelemetry. It overlaps with Bloomlife on maternal monitoring and RPM but as part of a much wider medtech portfolio.

TypeBroad incumbent
Description

GE Healthcare provides in-clinic and ambulatory fetal monitoring solutions and broader hospital-grade patient monitoring. It competes in the same clinical category as Bloomlife's fetal monitoring module but at a much larger, enterprise-hospital scale.

TypeEmerging player
Description

Ovia Health provides digital maternity and women's health programs to employers and health plans, including engagement, coaching, and some remote monitoring components. It is comparable to Bloomlife in serving the same maternal population but with a software/engagement-led approach rather than FDA-cleared devices.

TypeEmerging player
Description

Maven Clinic is a digital women's and family health platform offering virtual care across preconception, pregnancy, postpartum, and pediatrics, including partnerships with health plans and employers. It overlaps with Bloomlife in serving high-risk pregnant patients but delivers care through a virtual clinic model rather than FDA-cleared monitoring devices.

TypeDirect peer
Description

Vivify Health provides a remote patient monitoring platform with cellular-enabled devices, EMR integration, and condition-specific pathways. While not maternal-specific, its technology stack and reimbursement-driven RPM model are highly comparable to Bloomlife Connects.

TypeEmerging player
Description

iHealth Labs offers FDA-cleared cellular-enabled blood pressure monitors, glucose meters, and other connected devices used in consumer and RPM settings. It is comparable to Bloomlife on the hardware and cellular connectivity side but without an integrated maternal-care platform.

TypeEmerging player
Description

CareSimple is a remote patient monitoring vendor that provides cellular-enabled devices, EMR integration, and condition-specific programs for providers, including chronic disease management. It is comparable to Bloomlife in its RPM-as-a-service model targeting providers under CPT-based reimbursement.

TypeEmerging player
Description

MindChild Medical develops non-invasive fetal monitoring devices for clinical and potentially home use. It is comparable to Bloomlife in fetal heart rate monitoring technology but focuses on the in-clinic/hospital segment rather than a full RPM platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bloomlife

Maternal Health Remote Monitoringbloom-life.com

Bloomlife provides a cellular-enabled, FDA-cleared remote patient monitoring platform for high-risk pregnancies, targeting OB/GYNs, maternal-fetal medicine specialists, and US health systems with reimbursable blood pressure, blood glucose, and fetal monitoring.

What Bloomlife does

Bloomlife is a women's health technology company that has built a remote patient monitoring (RPM) platform for high-risk pregnancies. Founded in 2014 by Eric Dy and Julien Penders after Dy experienced a high-risk pregnancy in his own family, the company develops cellular-enabled, FDA-cleared medical devices for blood pressure, blood glucose, and patch-based fetal monitoring that transmit data directly to providers without requiring patient WiFi or smartphone apps. The core product, Bloomlife Connects, integrates these device modules with a Health Screening component (PHQ-9, EPDS, social determinants of health assessments), an AI-based digital biomarker for labor onset detection, configurable smart notifications, and native EMR integration.

The company targets OB/GYNs, maternal-fetal medicine specialists, women's health practices, and health systems in the United States, with engineering and clinical study operations in Liège, Belgium and Eindhoven, Netherlands. Its business model is reimbursement-driven: the RPM program is offered to providers at no upfront cost and no commitment, with device costs bundled into existing CPT-coded remote patient monitoring reimbursement covered by 19 in-network commercial payers plus Medicaid. Customer references include UCHealth, Ochsner Health System, Oregon Health Science University, Valley Perinatal Services, Unified Women's Healthcare, and Advantia Health.

Bloomlife has raised approximately $29M cumulatively across disclosed rounds from 2015 through September 2024, including a $12.9M round in September 2024, with investors including SOSV HAX, Plug and Play, Kapor Capital, Noshaq (Meusinvest), SFPIM, and RH Capital. The company holds 15 patents and 19 peer-reviewed publications supporting its clinical evidence base, has received FDA 510(k) clearance for its fetal monitor (K222327), and maintains SOC 2 Type II and HIPAA compliance for enterprise-grade deployment.

Bloomlife firmographics

Firmographics
Name
Bloomlife
Legal name
Bloomlife, Inc.
Website
https://bloom-life.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Bloomlife provides a cellular-enabled, FDA-cleared remote patient monitoring platform for high-risk pregnancies, targeting OB/GYNs, maternal-fetal medicine specialists, and US health systems with reimbursable blood pressure, blood glucose, and fetal monitoring.
Ownership category
akta.pro rank

Bloomlife industry classification

Industry
Product category
Maternal Health Remote Monitoring
SIC
Services-Home Health Care Services (8082)
akta.pro industry
PRIMARYHLALAFAG
Maternal & High-Risk Pregnancy Remote Monitoring (BP, glucose, fetal/uterine monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAPAG
Maternal, Neonatal & Pediatric Remote Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAF
Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Remote patient monitoring
  • Maternal health monitoring
  • Fetal heart monitoring
  • Connected care platform
  • Pregnancy care solutions

Where Bloomlife is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Bloomlife business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Remote Patient Monitoring Reimbursement: Bloomlife's primary revenue stream comes from Remote Patient Monitoring reimbursement covered by Medicaid and commercial payers using existing CPT codes. The program includes cellular-enabled FDA-cleared monitoring devices where the cost of devices (blood pressure cuff and blood glucose device) is included in the remote patient monitoring reimbursement with no additional costs charged to the practice or patient.
  2. Equity Securities Offering: SEC Form D filing indicates an exempt offering of securities raising approximately $14.9 million with equity securities and pooled investment fund interests.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractRPM Program for Healthcare Providers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Bloomlife product offering

Product offering

Core offering

Bloomlife provides a connected care platform, Bloomlife Connects, for remote patient monitoring of high-risk pregnancies. The offering combines FDA-cleared cellular-enabled medical devices for blood pressure, blood glucose, and patch-based fetal monitoring with cloud-based analytics, EMR integration, customizable clinical protocols, and AI-based digital markers for labor detection. The program is sold to healthcare providers and is reimbursable under existing CPT codes for remote patient monitoring.

Product overview

Bloomlife offers Bloomlife Connects, a comprehensive connected care platform for remote monitoring of high-risk pregnancies. The platform integrates multiple monitoring modules including Blood Pressure RPM (cellular-enabled, FDA-cleared blood pressure monitoring), Blood Glucose RPM (continuous glucose monitoring and finger stick support), Fetal Monitoring (patch-based home fetal non-stress testing with FDA 510(k) clearance), and Health Screening (PHQ-9 and EPDS mental health assessments). These modules work together to enable healthcare providers to assess maternal-fetal health outside the office, with automated data capture, configurable clinical protocols, smart notifications, and EMR integration.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bloomlife Connects A comprehensive connected care platform that enables healthcare providers to remotely monitor high-risk pregnant patients. Includes FDA-cleared cellular-enabled blood pressure and blood glucose monitoring devices, the world's first patch-based home fetal monitoring solution (FDA 510(k) #K222327), and digital health screening assessments (PHQ-9, EPDS). Features cloud-based analytics, customizable care escalation protocols, smart notifications, native EMR integration, and AI-based digital markers for labor detection. Designed for healthcare providers including OB/GYN practices, MFM specialists, and health systems, and is reimbursable using existing CPT codes for remote patient monitoring.

Quantifiable outcome

  • 260% improvement in adherence to home blood pressure screening with Bloomlife Connects compared to standard of care
  • +8 more outcomes

Companies that use Bloomlife

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Bloomlife technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature6 records

Bloomlife partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered advisory and customer.

  • March of DimesadvisoryStrategic or Co-development PartnerMarch of Dimes Chief Medical Officer Amanda Williams, MD, MPH serves as an advisor to Bloomlife, providing expertise in women's health and maternal care improvement.
  • Valley Perinatal ServicescustomerTechnology or IntegrationValley Perinatal Services is both a customer and advisory partner, with MFM Medical Director Ravi Gunatilake serving as a medical advisor. The practice uses Bloomlife Connects for remote monitoring of high-risk patients.
  • Louisiana Perinatal Quality CollaborativeadvisoryStrategic or Co-development PartnerMedical Director Veronica Gillispie-Bell, MD, MAS serves as a strategic advisor, bringing expertise in perinatal quality improvement and maternal health outcomes.
  • OrganonadvisoryStrategic or Co-development PartnerCharlotte Owens, MD, Head of Medical Affairs and Outcomes Research at Organon, serves as an advisor bringing pharmaceutical and women's health industry expertise.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Bloomlife competitors and assessment

Company assessment

Direct peers

  • Babyscripts: Babyscripts is a direct competitor offering a maternal remote patient monitoring platform for OB/GYN practices, including blood pressure monitoring, weight tracking, and virtual care. It targets the same provider customer base and reimbursement model as Bloomlife.
  • HeraMED: HeraMED develops remote fetal and maternal monitoring solutions, including at-home NST and contraction monitoring devices. It competes directly with Bloomlife in connected maternal-fetal monitoring for high-risk pregnancies.
  • Vivify Health (by Optum): Vivify Health provides a remote patient monitoring platform with cellular-enabled devices, EMR integration, and condition-specific pathways. While not maternal-specific, its technology stack and reimbursement-driven RPM model are highly comparable to Bloomlife Connects.

Broad incumbents

  • Philips (Philips Avent and BioTelemetry): Philips offers fetal monitoring hardware, maternal care solutions, and a broader remote patient monitoring portfolio through BioTelemetry. It overlaps with Bloomlife on maternal monitoring and RPM but as part of a much wider medtech portfolio.
  • GE Healthcare: GE Healthcare provides in-clinic and ambulatory fetal monitoring solutions and broader hospital-grade patient monitoring. It competes in the same clinical category as Bloomlife's fetal monitoring module but at a much larger, enterprise-hospital scale.

Emerging players

  • Ovia Health (by Labcorp): Ovia Health provides digital maternity and women's health programs to employers and health plans, including engagement, coaching, and some remote monitoring components. It is comparable to Bloomlife in serving the same maternal population but with a software/engagement-led approach rather than FDA-cleared devices.
  • Maven Clinic: Maven Clinic is a digital women's and family health platform offering virtual care across preconception, pregnancy, postpartum, and pediatrics, including partnerships with health plans and employers. It overlaps with Bloomlife in serving high-risk pregnant patients but delivers care through a virtual clinic model rather than FDA-cleared monitoring devices.
  • iHealth Labs: iHealth Labs offers FDA-cleared cellular-enabled blood pressure monitors, glucose meters, and other connected devices used in consumer and RPM settings. It is comparable to Bloomlife on the hardware and cellular connectivity side but without an integrated maternal-care platform.
  • CareSimple: CareSimple is a remote patient monitoring vendor that provides cellular-enabled devices, EMR integration, and condition-specific programs for providers, including chronic disease management. It is comparable to Bloomlife in its RPM-as-a-service model targeting providers under CPT-based reimbursement.
  • MindChild Medical: MindChild Medical develops non-invasive fetal monitoring devices for clinical and potentially home use. It is comparable to Bloomlife in fetal heart rate monitoring technology but focuses on the in-clinic/hospital segment rather than a full RPM platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Bloomlife social profiles

Digital presence

Bloomlife compliance and trust

Trust signal

Compliance3 records

Bloomlife financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bloomlife leadership team

Management profile

Number of profiles

Profiles8 records

Bloomlife funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bloomlife M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bloomlife

What does Bloomlife do?

Bloomlife provides a connected care platform, Bloomlife Connects, for remote patient monitoring of high-risk pregnancies. The offering combines FDA-cleared cellular-enabled medical devices for blood pressure, blood glucose, and patch-based fetal monitoring with cloud-based analytics, EMR integration, customizable clinical protocols, and AI-based digital markers for labor detection. The program is sold to healthcare providers and is reimbursable under existing CPT codes for remote patient monitoring.

Is Bloomlife a public or private company?

Bloomlife is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bloomlife founded?

Bloomlife was founded in 2014. It employs 11 to 50 people.

Where is Bloomlife based?

Bloomlife is headquartered in San Francisco, United States, in the North America region.

How does Bloomlife make money?

Two revenue lines are on record. Remote Patient Monitoring Reimbursement is the primary driver. The others are equity Securities Offering.

Who are Bloomlife's main competitors?

Direct peers on record are Babyscripts, HeraMED and Vivify Health (by Optum). Broad incumbents are Philips (Philips Avent and BioTelemetry) and GE Healthcare. Emerging players are Ovia Health (by Labcorp), Maven Clinic, iHealth Labs, CareSimple and MindChild Medical.

Does Bloomlife have an API?

No public API is recorded for Bloomlife.

What industry is Bloomlife in?

Bloomlife's product category is Maternal Health Remote Monitoring. Its primary akta.pro industry code is HLALAFAG, Maternal & High-Risk Pregnancy Remote Monitoring (BP, glucose, fetal/uterine monitoring), with a secondary code of HLACAPAG, Maternal, Neonatal & Pediatric Remote Monitoring. Its SIC code is 8082.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmExecBloomlife’s Maternal and Fetal Monitoring Device Receives FDA ApprovalThe FDA has approved Bloomlife’s MFM-Pro, the company's first prescription-based maternal and fetal monitoring device designed for home or clinic use. This regulatory milestone marks Bloomlife's strategic transition from consumer wearables to medical markets, following a partnership with Perigen to enhance high-risk pregnancy monitoring. The approval aims to shift maternal care towards cost-effective, patient-centered home settings to address rising maternal mortality rates.Nelson Advisors BlogParadigm Shift in Medical Wearables: From Macro Electronics to Flexible Biochemical BiosensorsNelson Advisors published an industry analysis on the shift from rigid macroelectronics to flexible biochemical biosensors in medical wearables, highlighting how GLP-1 therapeutics growth is driving demand for continuous metabolic monitoring via skin-conformal devices using microfluidics, BioMEMS, and microneedle arrays. The report identifies a physician-patient adoption paradox, noting that while 77% of U.S. physicians acknowledge clinical utility of continuous wearable data, only 15% of patients proactively share insights with care teams, citing reimbursement gaps, data fatigue, and EHR integration challenges. Key applications covered include continuous glucose monitoring (Abbott FreeStyle Libre, Dexcom Stelo), remote prenatal care (Nuvo INVU, Bloomlife), and athletic performance tracking (PointFit), with North America holding 45% of the global wearable biosensor market.FortunebusinessinsightsFetal Monitoring Market Size, ShareThe global fetal monitoring market was valued at USD 3.11 billion in 2024 and is projected to grow to USD 4.85 billion by 2032, exhibiting a CAGR of 5.7% during the forecast period, with North America dominating the market with a 34.40% share in 2024. Market growth is driven by increasing high-risk pregnancies, rising maternal age, growing C-section rates, and demand for continuous real-time monitoring during labor, while regulatory scrutiny and accuracy concerns in non-invasive monitoring present challenges. Key industry developments include Bloomlife's USD 12.2 million fundraising in November 2024 and multiple FDA clearances for wireless monitoring solutions, with companies focusing on AI-driven interpretation tools and cloud-based data sharing for remote obstetric review.PharmiWeb.comGlobal FemTech Market to grow at 16% CAGR, driven by digital health, startups & demand by 2030The global FemTech market is projected to grow at a 16% CAGR over the next five years, driven by rising women's health awareness, digital health advancements, and demand for personalized care. The market spans reproductive health, fertility tracking, and menopause management, with key players including Flo Health and Bloomlife.Plugandplaytechcenter5 Femtech Companies Improving Women-Centric HealthcareThe article highlights five femtech companies—Ava, Bloomlife, Flo.Health, and Kindbody—that are leveraging technology to improve women's healthcare. These entities offer specialized solutions ranging from fertility tracking wearables and prenatal monitoring to AI-driven cycle prediction and comprehensive fertility services.FieldtexcasesClinical-Grade vs. Consumer Wearables: What Sets Them Apart?This article compares consumer-grade wearables (such as Fitbit and Apple Watch) with clinical-grade medical devices, explaining how FDA-approved clinical wearables offer superior accuracy, real-time monitoring, and treatment capabilities for chronic disease management. It profiles four FDA-approved clinical wearables—Biotricity Bioflux, Medtronic MiniMed 770G, NeuroMetrix Quell, and Bloomlife—and notes the growing market for medical-grade wearables driven by chronic disease rates and remote monitoring demand. The article serves as promotional content for Fieldtex Cases, a manufacturer of sewn components for medical wearable devices.openPR.comFemTech Market Size, Share, and Trends Report | Set for 16% CAGR by 2030The global FemTech market is projected to grow at a 16% CAGR over the next five years, driven by rising women's health awareness, digital health advancements, and government initiatives. The market encompasses reproductive health, fertility tracking, and menopause management, with key players including Flo Health and Bloomlife.Castle PlacementTop 10 DigitalHealth/HealthTech Capital Raises in the U.S.This article lists the top ten DigitalHealth and HealthTech capital raises in the U.S. between September 2nd and 15th, 2024, highlighting funding rounds for companies such as Bloomlife, XP Health, and Vesta Healthcare. The report details specific investment amounts and lead investors for these transactions, ranging from seed rounds to Series B funding. It serves as a market overview of recent venture capital activity within the sector.SecSEC FORM DBloomlife, Inc. filed a Form D with the SEC to announce an exempt offering of Series B Preferred Stock and Common Stock under Rule 506(b). The company reported total offering proceeds of $14,886,953 USD, with $12,929,458 already sold to 50 investors as of late August 2024.YahooFemale Health Tech market is estimated to grow at a CAGR of 9.6% by 2034: VisiongainVisiongain estimates the global female health tech market will reach US$140.9 billion by 2034, growing at a 9.6% CAGR from 2024 to 2034. The report covers product types, applications, regional analysis, and key players, including recent FDA clearance for Bloomlife's maternal monitoring device.